Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats
Rachel R. Horsley, Tomáš Páleníček, Jan Kolin, Karel Valeš
Behavioural Pharmacology March 13, 2018 DOI: 10.1097/fbp.0000000000000394 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Sample size | 40 |
| Population | Wistar rats |
| Interventions | Ketamine Psilocin |
| Dose | 0.5 or 3 mg/kg ketamine; 0.05 or 0.075 mg/kg psilocin |
| Duration | 6-day intervention, elevated plus-maze test 48 hours after final treatment |
| Topics | Anxiety Ketamine Serotonin Esketamine Microdosing Psilocybin |
| Keywords | Pharmacology Analysis of variance Hallucinogen Elevated plus maze Nmda receptor Anesthesia |
| Citations | 52 |
| Key findings | Microdosing with ketamine or psilocin produced a mildly anxiogenic profile in rats, suggesting that microdosing for therapeutic purposes might be counter-productive. |
Abstract
Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent 'microdosing' (usually one-tenth of a 'full' active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to show its lasting effects. The objective of this study was to test for lasting effects on anxiety in rats after microdosing with ketamine or psilocin. Over 6 days, Wistar rats (N=40) were administered ketamine (0.5 or 3 mg/kg), psilocin (0.05 or 0.075 mg/kg), or saline on three occasions. A 5-min elevated plus-maze test was conducted 48 h after the final drug treatment (n=8). Dependent variables were entries (frequency), spent time (%), and distance traveled (cm) in each zone, as well as total frequency of rears, stretch-attend postures, and head dips. Statistical analyses of drug effects used separate independent one-way analysis of variance and pair-wise comparisons using independent t-tests. Statistical effects were modest or borderline and were most consistent with a mildly anxiogenic profile, which was significant at lower doses; however, this conclusion remains tentative. The lower doses of ketamine and psilocin produced comparable effects (to one another) across each variable, as did the higher doses. This pattern of effects may suggest a common (e.g. neurotransmitter/receptor) mechanism. We conclude that microdosing with hallucinogens for therapeutic purposes might be counter-productive; however, more research is needed to confirm our findings and to establish their translational relevance to clinical 'psychedelic' therapy.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Intermittent microdoses of psilocin or ketamine produced a mildly anxiogenic profile in rats, most significant at lower doses, though the conclusion was tentative.
Synthesized
Comparable studies
Other preclinical and animal studies on psilocybin and microdosing, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Rats | 2023 | Experimental study | |
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. Adult male Wistar rats | 2026 | Preclinical experimental study | |
| Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice. Male C57BL/6J mice | 2026 | Experimental study |
Citations in the library
Cited by 44
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers Biological Psychiatry June 3, 2019
- Chronic, Intermittent Microdoses of the Psychedelic N , N -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents ACS Chemical Neuroscience March 4, 2019
- Motives and Side-Effects of Microdosing With Psychedelics Among Users The International Journal of Neuropsychopharmacology May 30, 2019
and 39 more in the library
Cites 22
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats Science August 28, 1998
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
- Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) CNS Neuroscience & Therapeutics April 10, 2013
- The pharmacology of psilocybin Addiction Biology October 1, 2002
and 17 more in the library